3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Lymphoma, Large B-Cell, Diffuse
43
Breast Neoplasms
29
Lymphoma
28
Sarcoma
26
Hodgkin Disease
24
Triple Negative Breast Neoplasms
20
Burkitt Lymphoma
20
Precursor Cell Lymphoblastic Leukemia-Lymphoma
18
Lymphoma, Follicular
17
Neoplasms
15
Ovarian Neoplasms
14
Lymphoma, Non-Hodgkin
13
Lymphoma, B-Cell
13
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
10
Lymphoma, T-Cell, Peripheral
9
Endometrial Neoplasms
9
Neuroblastoma
7
Neoplasm Metastasis
7
Lymphoma, Mantle-Cell
7
Liposarcoma
7
Leukemia
7
Fallopian Tube Neoplasms
7
Recurrence
6
Multiple Myeloma
6
Leiomyosarcoma
6
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
5
Lymphoma, B-Cell, Marginal Zone
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Leukemia, Biphenotypic, Acute
5
Inflammatory Breast Neoplasms
5
Interventions
fludarabine
2
Paclitaxel
2
Gemcitabine
2
Bevacizumab
2
pembrolizumab
1
liposomal doxorubicin
1
dostarlimab
1
Taxes
1
Stem Cell Transplantation
1
Sirolimus
1
Nivolumab
1
Melphalan
1
Ipilimumab
1
Immunoglobulin G
1
Doxorubicin
1
Docetaxel
1
Disulfides
1
Dexamethasone
1
Carboplatin
1
Busulfan
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma, Clear Cell
×
Doxorubicin
×
1 year
×
Clear all
NCT06023862
2026-05-06
DOVE
Yonsei University
Phase 2
Recruiting
198 enrolled